Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about a user who experienced hair growth after three months of using Minoxidil and plans to start Finasteride soon. The user is considering a hair transplant next year and is curious about the potential for further growth.

A 27-year-old male experiencing hair loss at Norwood 3 level has tried minoxidil and finasteride but stopped finasteride due to side effects. He is exploring alternatives like Dermapen, Regenepure DR Shampoo, saw palmetto, and considering aromatase inhibitors for managing side effects, while also seeking advice on DHT blockers.

The user has been using finasteride for a year and dutasteride for three months with no significant progress in hair regrowth, despite also using minoxidil, low light therapy, and anti-dandruff shampoo. They are considering a hair transplant and exploring other potential causes of hair loss, such as inflammation or thyroid issues, and are advised to consult a dermatologist and consider oral minoxidil.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

A user discusses their hormone blood test results before starting finasteride for hair loss, noting high DHT and estradiol levels. They tried topical finasteride for a few days but felt tired.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The user experienced significant hair growth over three months using topical Minoxidil, microdosing Finasteride, microneedling, and ketoconazole shampoo. They also use Toppik hair fibers and Aveda hair thickening tonic for styling.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses hair loss treatment progress using 1 mg finasteride and 2 mg oral minoxidil daily. The user reports increased body hair as a side effect.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

A 45-year-old man is using oral finasteride, oral minoxidil, tretinoin, and microneedling for hair regrowth, with plans to add topical dutasteride to improve his hairline. He is considering a hair transplant but is cautious about changing his current regimen.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.

The conversation discusses using tretinoin as an additional treatment for hair loss alongside minoxidil, with plans to test its effectiveness by applying it to only one side of the scalp. The user intends to start this experiment after using minoxidil for a year.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The conversation discusses hair loss treatments using topical finasteride (0.25) and minoxidil (5%) daily, with mixed opinions on effectiveness. Some users report maintenance and thickening, while others see no significant change.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.

The user is pleased with hair regrowth after taking daily tablets of 1.1 mg finasteride, 3 mg minoxidil, and 2.5 mg biotin for 3 months, with no side effects and some light shedding. The most noticeable improvement is at the crown, which was the main concern.

A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

People with diffuse thinning and retrograde hair loss are discussing treatments like finasteride, minoxidil, and dutasteride, with some reporting improvements and others experiencing issues like scalp inflammation and increased sebum. Suggestions include addressing scalp inflammation, considering gut health, and possibly using topical antiandrogens or micro-needling.

The user regrew hair using minoxidil and microneedling but lost results despite using DHT blockers. They are inquiring if adding tretinoin improved results for others.

The user is taking finasteride and minoxidil for hair loss, but their DHT levels are unusually high, leading to suspicion of lab errors. They plan to retest at a different lab to confirm results.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

The user has been using oral finasteride and topical minoxidil for years and recently started 2.5 mg oral minoxidil, with no significant regrowth observed yet. They are considering adding tretinoin cream to their regimen but are concerned about potential shedding.